Kamis, 30 November 2023

Green in the Red Zone: Why Bristol-Myers Could Jump 80% From Here

I see great gains ahead from BMY's product portfolio despite patent-cliff fears and the Ozempic craze. Plus: an update on OGN.
To view this email as a web page, go here.
©2023 TradeSmith, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of TradeSmith, LLC. This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as researchers and writers. Our work may contain errors and should not be considered personalized investment advice. TradeSmith, LLC does not issue securities recommendations, and no discussion of a particular stock(s) should be interpreted as such. Past, simulated, and/or hypothetical performance of any strategy published by TradeSmith, LLC should not be interpreted as representational of future returns. You shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility.
This email was sent to: indra21poetra@gmail.com

This email was sent by: TradeSmith
PO Box 3039, Spring Hill, FL, 34611, US


We respect your right to privacy - view our policy

Tidak ada komentar:

Posting Komentar